Many primary care docs don't know long-term effects of chemo: survey

May 17, 2012 By Amanda Gardner, HealthDay Reporter
Many primary care docs don't know long-Term effects of chemo: survey
Experts stress that information needs to be passed on after cancer treatment ends.

(HealthDay) -- Many primary care doctors don't know the long-term side effects of the chemotherapy treatments that cancer survivors under their care may have been given, a new survey found.

On the other hand, most oncologists -- though not all -- are familiar with the side effects of four common treatments used to treat breast and colon , according to the results of the survey being presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

"While oncologists commonly identify the main late effects of four common , primary care providers did not," study author Dr. Larissa Nekhlyudov said during a Wednesday news conference. "This is not surprising in that primary care providers have different training and exposure to chemotherapy drugs," she noted.

"However, these findings emphasize that in the transition of from oncology to primary care settings, primary care providers should be informed of late effects of cancer treatments so they are better prepared to recognize and address these effects," added Nekhlyudov, who is an assistant professor of population medicine at Harvard Medical School.

Advances in have pushed the number of in the United States from 3 million in the 1970s to 12 million today.

Once cancer treatments -- such as chemotherapy or radiation -- are complete, primary care physicians become a critical part of continuing care for cancer survivors.

The new findings are based on a 2009 survey of more than 1,100 primary care doctors and more than 1,100 oncologists (doctors who specialize in cancer) across the United States.

Both types of doctors were asked to identify side effects of four commonly used for breast and : Adriamycin (); Eloxatin (); Cytoxan (cyclophosphamide); and Taxol (paclitaxel).

Fifty-five percent of primary care doctors identified heart problems as a late-occurring effect of Adriamycin, while only 27 percent and 22 percent identified peripheral neuropathy (nerve damage to the arms and legs) as a possible result of Taxol and Eloxatin, respectively.

Only 15 percent to 17 percent of primary care doctors knew that early menopause and second cancers could result from Cytoxan.

Oncologists performed better on the survey, with 62 percent to 97 percent aware of these late effects.

It was "surprising that oncologists were not more aware of late effects," Nekhlyudov said. But she also pointed out that the area of cancer survivorship is relatively new.

"As more and more attention is placed on survivorship, oncologists will become more equipped with that information," she said.

The findings highlight the need for more communication between the different doctors involved in a patient's care, one expert stressed.

The burden of that communication lies not only with doctors ( and ) but also with patients, said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.

"This study just highlights the importance of communication on everyone's part, including the patient, including the doctors in trying to get that information across," she added. "If an oncologist is discharging a patient, they should make it clear what they need to be looking for in the future and that they need to convey this to their doctor."

The knowledge rates shown here make "a good case for electronic medical records . . . which would allow providers to access patients' cancer care," said ASCO spokesman Dr. Nicholas Vogelzang.

A second study being presented at the ASCO meeting in June found that the antipsychotic drug Zyprexa (olanzapine), used to treat schizophrenia and bipolar disorder, reduced post-chemotherapy nausea and vomiting among patients who had not responded to other therapies.

Eighty patients with chemotherapy-related nausea and vomiting were randomized to receive either Zyprexa or the heartburn drug Reglan (metoclopramide), often used to treat nausea and vomiting in cancer patients.

Over the next three days, 71 percent of patients taking Zyprexa did not vomit, compared with 32 percent of patients receiving Reglan.

About two-thirds of patients on Zyprexa experienced no nausea, compared with only one-quarter of Reglan patients, the study found.

Zyprexa can cause side effects if used for six months or longer, but did not cause significant for the short duration used in this study. Generally, those getting chemotherapy would not need to take Zyprexa for longer than three days.

The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

Explore further: Study: Doctors differ in how best to care for America's 12 million cancer survivors

More information: The U.S. National Cancer Institute has more on chemotherapy.

Related Stories

Study: Doctors differ in how best to care for America's 12 million cancer survivors

July 25, 2011
There are major differences between oncologists and primary care physicians regarding knowledge, attitudes, and practices required to care for American's 12 million cancer survivors. That is the key finding of the first ...

Breast cancer patients more satisfied when specialists share care management

December 15, 2011
Patients with breast cancer report greater satisfaction with care when their cancer doctor co-manages their care with other specialists. However, some specialists are more likely than others to share decision-making with ...

Most cancer physicians reach out to bereaved family, caregivers

October 3, 2011
While the majority (70 percent) of surveyed cancer care physicians initiate contact with the bereaved family and caregivers of their patients who have died, over two-thirds do not feel they have received adequate training ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

DanielHaszard
not rated yet May 17, 2012
Regarding Zyprexa as anti-nausea treatment.Doesn't 50 year old Thorazine do the same at 1/10 the dosage cost? Thorazine is so effective that it is used by veterinarians.
In the news now,the Feds and the States are prosecuting the profit driven drug companies left and right for violations that have directly caused hundreds of deaths and thousands of disabilities.My personal experience was with Eli Lilly Zyprexa-Daniel Haszard
FMI Google-Haszard Zyprexa
*tell the truth don't be afraid*


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.